Medivo changes name to Prognos
Healthcare data analytics company Medivo has renamed itself as Prognos, following six years of research and development of clinical diagnostic solutions.
Prognos CEO Sundeep Bhan said in a statement that launching Prognos elevates the company’s ability to leverage its lab results database to glean clinical insights for earlier tracking and prediction of diseases.
Through a collaboration with Biogen, Cigna, LabCorp and Quest Diagnostics, the company now offers the Prognos Registry of 5 billion clinical records for 100 million patients in more than 30 disease areas. The registry enables earlier identification of patients who can benefit from enhanced treatment decision-making, risk management, and quality improvement under the HEDIS guidelines.
During its R&D phase as Medivo, Prognos explored clinical diagnostic assets, which has resulted in development of AI and HIPAA-compliant advanced analytics with more than 500 proprietary and learning clinical algorithms, the company said.
Health insurers can now leverage Prognos' solutions to engage with providers earlier in the patient treatment process to improve quality of care, the company said, while life sciences organizations can use Prognos products to determine complex patient journeys and help brands dependent on biomarkers commercialize highly targeted patient selection strategies for the treating physicians.
And diagnostics organizations also can partner with Prognos to leverage their lab data and clinical and technology expertise with Prognos analytic solutions to inform physicians and increase the likelihood that patients can access the treatments that will improve outcomes, the company added.